Uncovering women's health signatures from the endometrium
Research type
Research Study
Full title
Harnessing the disease signatures from endometrium and menstrual blood to identify avenues for the treatment of chronic conditions such as endometriosis and related pathologies.
IRAS ID
358037
Contact name
Léa Wenger
Contact email
Sponsor organisation
Cycle Therapeutics Ltd
Clinicaltrials.gov Identifier
Duration of Study in the UK
5 years, 0 months, 0 days
Research summary
Many women’s health conditions have limited treatments available and poor outcomes, in part due to the lack of understanding of disease processes and lack of data available. This study aims to build knowledge in women’s health by leveraging the information we can gather from menstrual fluid and the uterus. By looking at samples from menstrual fluid and associating them with health outcomes of the people donating these samples, we will be able to find new signatures of disease. This can help us find early diagnostic markers, better classify diseases and give us the tools that allow us to build the right models in the lab to find new treatments. By collecting this data, we will be able to identify patterns within given diseases that can help us cure them. The study is funded and undertaken by Cycle Therapeutics, a company with the mission of curing endometriosis. All women above the age of 16 will be eligible, although most samples will be collected from those who are menstruating. Women with endometriosis or suspicion of the disease are encouraged to take part, but participation of people without any symptoms or conditions is important to understand what the base healthy state looks like. Most of the sample processing will be done within Cycle and collection will occur at clinics or remotely, and can be as simple as pouring menstrual fluid from a cup into a tube to ship to Cycle. The study will last five years, during which we hope to build a strong understanding of conditions affecting women. We will be able to provide health insight to donors after each donation, but the greatest value in this study will lie in the new treatments we can discover thanks to our novel understanding.
REC name
South West - Frenchay Research Ethics Committee
REC reference
25/SW/0088
Date of REC Opinion
14 Aug 2025
REC opinion
Unfavourable Opinion